Israel

BMI View: We view the Israeli pharmaceutical market as the most attractive investment opportunity to multinationals in the Gulf Levant. A largely urbanised population, with less than... 2012-11-14

BMI View: Despite an overall good performance of its branded and generic drug sales in emerging and developed markets, Teva Pharmaceutical fell victim to currency fluctuations in Q212.... 2012-08-10

BMI View: We expect Israel's second-largest health management organisation (HMO), Maccabi Health Services, to slightly outperform its rivals over the short-to-medium term. This service... 2012-07-20

BMI View: While Israel claims its very efficient healthcare system means it does not need to spend as much of its GDP on provision (7.2% in 2010), in reality the government's fiscal... 2012-06-25

BMI View: While Teva's Q112 results were not terrible compared to Q411, as revenues and profits both saw reasonable growth, and considering the recent acquisitions of Cephalon and Taiyo,... 2012-05-10

BMI View: Israel will continue to attract investment because of a strong culture of entrepreneurism that has led to a large number of life science start-up companies. In particular,... 2012-04-27

BMI View: Following widespread protests in mid-2011, the Israeli government has been under significant pressure to spend more on housing, healthcare and education. While it was not... 2012-02-17